Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br STAR METHODS br Detailed methods are provided

    2020-03-17


    STAR+METHODS
    Detailed methods are provided in the online version of this paper and include the following:
    d KEY RESOURCES TABLE
    d CONTACT FOR REAGENT AND RESOURCE SHARING d METHOD DETAILS
    B Definition of the secretome and SP genes B The experimentally-derived secretome B Retrieval of human plasma proteome data B Transcriptomic data retrieval
    B Mutation burden quantification
    B Analysis of high-purity tumor samples
    B Consensus biomarker score
    B Core secretome definition and analysis B Definition of tissue-specific genes
    B Estimation of UPR activation
    B Glycosylation and disulfide bond redox B Secretory burden (SB) score
    d QUANTIFICATION AND STATISTICAL ANALYSIS B Differential Epirubicin HCl (DE) analysis
    B Gene set analysis
    B Adjustment of p values
    SUPPLEMENTAL INFORMATION
    Supplemental Information can be found with this article online at https://doi.
    ACKNOWLEDGMENTS
    The authors thank Daniel Cook for valuable discussions. Research reported in this publication was supported by funding from the Knut and Alice Wallenberg Foundation and the National Cancer Institute of the NIH under Epirubicin HCl award number F32CA220848. The results shown here are in part based upon data generated by TCGA Research Network (https://cancergenome.nih.gov/). The GTEx Proj-ect was supported by the Common Fund of the Office of the Director of the NIH, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The GTEx data used for the analyses described in this article were obtained from the GTEx Portal on October 18, 2017.
    AUTHOR CONTRIBUTIONS
    DECLARATION OF INTERESTS
    The authors declare no competing interests.
    REFERENCES
    Avile´s-Va´zquez, S., Cha´vez-Gonza´lez, A., Hidalgo-Miranda, A., Moreno-Lor-enzana, D., Arriaga-Pizano, L., Sandoval-Esquivel, M.A., Ayala-Sa´nchez, M., Aguilar, R., Alfaro-Ruiz, L., and Mayani, H. (2017). Global gene expression pro-files of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib. Cancer Med. 6, 2942–2956.
    urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol.
    Bager, C.L., Willumsen, N., Leeming, D.J., Smith, V., Karsdal, M.A., Dornan, D., and Bay-Jensen, A.C. (2015). Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy con-trols: a preliminary study. Cancer Biomark. 15, 783–788.
    Feizi, A., Gatto, F., Uhlen, M., and Nielsen, J. (2017). Human protein secretory pathway genes are expressed in a tissue-specific pattern to match processing demands of the secretome. NPJ Syst. Biol. Appl. 3, 22.
    Huang, X., Stern, D.F., and Zhao, H. (2016). Transcriptional Profiles from Paired Normal Samples Offer Complementary Information on Cancer Patient Survival–Evidence from TCGA Pan-Cancer Data. Sci. Rep. 6, 20567.
    Kulasingam, V., and Diamandis, E.P. (2008). Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 5, 588–599.
    Mroczko, B., Koz1owski, M., Groblewska, M., qukaszewicz, M., Niklinski, J., Jelski, W., Laudanski, J., Chyczewski, L., and Szmitkowski, M. (2008). The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients. Clin. Chim. Acta 389, 61–66.
    Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer.
    Papaleo, E., Gromova, I., and Gromov, P. (2017). Gaining insights into cancer biology through exploration of the cancer secretome using proteomic and bio-informatic tools. Expert Rev. Proteomics 14, 1021–1035.
    Prassas, I., Chrystoja, C.C., Makawita, S., and Diamandis, E.P. (2012). Bio-informatic identification of proteins with tissue-specific expression for biomarker discovery. BMC Med. 10, 39.